Medline (MDLN) Financials

$37.70 +1.68 (+4.66%)

Closing price 04:00 PM Eastern

Extended Trading

$37.82 +0.12 (+0.32%)

As of 05:18 PM Eastern

Annual Income Statements for Medline

This table shows Medline's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	234	1,200	1,159
Consolidated Net Income / (Loss)	234	1,200	1,157
Net Income / (Loss) Continuing Operations	234	1,200	1,157
Total Pre-Tax Income	264	1,246	1,248
Total Operating Income	1,250	2,146	2,212
Total Gross Profit	5,885	6,976	7,518
Total Revenue	23,231	25,507	28,432
Operating Revenue	23,231	25,507	28,432
Total Cost of Revenue	17,346	18,531	20,914
Operating Cost of Revenue	17,346	18,531	20,914
Total Operating Expenses	4,635	4,830	5,306
Selling, General & Admin Expense	3,867	4,108	4,524
Amortization Expense	662	685	704
Other Operating Expenses / (Income)	106	37	78
Total Other Income / (Expense), net	-986	-900	-964
Interest & Investment Income	-976	-864	-812
Other Income / (Expense), net	-10	-36	-152
Income Tax Expense	30	46	91
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	0.00	-2.00
Basic Earnings per Share	$0.00	$0.00	($0.01)
Weighted Average Basic Shares Outstanding	0.00	0.00	810M
Diluted Earnings per Share	$0.00	$0.00	($0.01)
Weighted Average Diluted Shares Outstanding	0.00	0.00	810M
Weighted Average Basic & Diluted Shares Outstanding	-	-	1.31B

This table shows Medline's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q1 2026
Period end date	3/29/2025	3/28/2026
Net Income / (Loss) Attributable to Common Shareholders	322	129
Consolidated Net Income / (Loss)	322	239
Net Income / (Loss) Continuing Operations	322	239
Total Pre-Tax Income	338	291
Total Operating Income	571	422
Total Gross Profit	1,824	1,841
Total Revenue	6,644	7,352
Operating Revenue	6,644	7,352
Total Cost of Revenue	4,820	5,511
Operating Cost of Revenue	4,820	5,511
Total Operating Expenses	1,253	1,419
Selling, General & Admin Expense	1,070	1,228
Amortization Expense	175	176
Other Operating Expenses / (Income)	8.00	15
Total Other Income / (Expense), net	-233	-131
Interest & Investment Income	-210	-136
Other Income / (Expense), net	-23	5.00
Income Tax Expense	16	52
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	110
Basic Earnings per Share	$0.00	$0.16
Weighted Average Basic Shares Outstanding	0.00	819.08M
Diluted Earnings per Share	$0.00	$0.16
Weighted Average Diluted Shares Outstanding	0.00	824.84M
Weighted Average Basic & Diluted Shares Outstanding	-	1.31B

This table details how cash moves in and out of Medline's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	714	-3,737	-645
Net Cash From Operating Activities	1,685	1,769	1,744
Net Cash From Continuing Operating Activities	1,217	-631	-570
Net Income / (Loss) Continuing Operations	0.00	0.00	0.00
Depreciation Expense	951	977	1,011
Amortization Expense	170	82	59
Non-Cash Adjustments To Reconcile Net Income	-103	-1,015	-857
Changes in Operating Assets and Liabilities, net	199	-675	-783
Net Cash From Investing Activities	-312	-1,493	-474
Net Cash From Continuing Investing Activities	-312	-1,493	-474
Purchase of Property, Plant & Equipment	-275	-354	-447
Acquisitions	-26	-1,136	-27
Other Investing Activities, net	-11	-3.00	0.00
Net Cash From Financing Activities	-191	-1,613	399
Net Cash From Continuing Financing Activities	-191	-1,613	399
Repayment of Debt	-77	-16,173	-11,840
Repurchase of Common Equity	0.00	-20	-2,039
Payment of Dividends	-114	-1,518	-518
Issuance of Debt	0.00	16,098	7,748
Issuance of Common Equity	0.00	0.00	7,048
Cash Interest Paid	1,126	1,022	944
Cash Income Taxes Paid	52	101	62

This table details how cash moves in and out of Medline's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q1 2026
Period end date	3/29/2025	3/28/2026
Net Change in Cash & Equivalents	259	64
Net Cash From Operating Activities	682	412
Net Cash From Continuing Operating Activities	360	173
Net Income / (Loss) Continuing Operations	0.00	0.00
Depreciation Expense	247	254
Amortization Expense	15	11
Non-Cash Adjustments To Reconcile Net Income	97	32
Changes in Operating Assets and Liabilities, net	1.00	-124
Net Cash From Investing Activities	-92	-96
Net Cash From Continuing Investing Activities	-92	-96
Purchase of Property, Plant & Equipment	-98	-96
Acquisitions	6.00	0.00
Net Cash From Financing Activities	-9.00	-13
Net Cash From Continuing Financing Activities	-9.00	-13
Repayment of Debt	-179	0.00
Repurchase of Common Equity	-9.00	-3.00
Payment of Dividends	0.00	-10
Issuance of Debt	179	0.00
Cash Interest Paid	136	61

This table presents Medline's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2025
Period end date	12/31/2024	12/31/2025
Total Assets	35,978	38,484
Total Current Assets	8,272	10,679
Cash & Equivalents	199	1,939
Accounts Receivable	3,219	3,533
Inventories, net	4,456	4,769
Other Current Assets	398	438
Plant, Property, & Equipment, net	4,595	4,778
Total Noncurrent Assets	23,111	23,027
Goodwill	8,065	8,079
Intangible Assets	14,559	13,893
Noncurrent Deferred & Refundable Income Taxes	0.00	583
Other Noncurrent Operating Assets	487	472
Total Liabilities & Shareholders' Equity	35,978	38,484
Total Liabilities	19,454	19,198
Total Current Liabilities	2,440	2,490
Short-Term Debt	78	77
Accounts Payable	869	961
Accrued Expenses	1,493	1,452
Total Noncurrent Liabilities	17,014	16,708
Long-Term Debt	16,416	12,484
Noncurrent Deferred & Payable Income Tax Liabilities	0.00	3,542
Other Noncurrent Operating Liabilities	598	682
Commitments & Contingencies	0.00	0.00
Total Equity & Noncontrolling Interests	0.00	19,286
Total Preferred & Common Equity	0.00	10,737
Preferred Stock	0.00	0.00
Total Common Equity	16,158	10,737
Common Stock	16,147	10,717
Retained Earnings	0.00	-7.00
Accumulated Other Comprehensive Income / (Loss)	11	27
Noncontrolling Interest	0.00	8,549

This table presents Medline's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2026
Period end date	3/28/2026
Total Assets	39,014
Total Current Assets	11,180
Cash & Equivalents	2,236
Accounts Receivable	3,674
Inventories, net	4,807
Other Current Assets	463
Plant, Property, & Equipment, net	4,758
Total Noncurrent Assets	23,076
Goodwill	8,076
Intangible Assets	13,717
Noncurrent Deferred & Refundable Income Taxes	837
Other Noncurrent Operating Assets	446
Total Liabilities & Shareholders' Equity	39,014
Total Liabilities	19,665
Total Current Liabilities	2,536
Short-Term Debt	77
Accounts Payable	932
Accrued Expenses	1,527
Total Noncurrent Liabilities	17,129
Long-Term Debt	12,495
Noncurrent Deferred & Payable Income Tax Liabilities	4,009
Other Noncurrent Operating Liabilities	625
Commitments & Contingencies	0.00
Total Equity & Noncontrolling Interests	19,349
Total Preferred & Common Equity	11,272
Preferred Stock	0.00
Total Common Equity	11,272
Common Stock	11,132
Retained Earnings	122
Accumulated Other Comprehensive Income / (Loss)	18
Noncontrolling Interest	8,077

This table displays calculated financial ratios and metrics derived from Medline's official financial filings.

Metric	2023	2024	2025
Period end date	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	0.00	0.00
DEI Adjusted Shares Outstanding	0.00	0.00	0.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	0.00
Growth Metrics	-	-	-
Revenue Growth	0.00%	9.80%	11.47%
EBITDA Growth	0.00%	34.22%	-1.23%
EBIT Growth	0.00%	70.16%	-2.37%
NOPAT Growth	0.00%	86.54%	-0.78%
Net Income Growth	0.00%	412.82%	-3.58%
EPS Growth	0.00%	0.00%	0.00%
Operating Cash Flow Growth	0.00%	4.99%	-1.41%
Free Cash Flow Firm Growth	0.00%	0.00%	116.13%
Invested Capital Growth	0.00%	0.00%	-8.87%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-
Gross Margin	25.33%	27.35%	26.44%
EBITDA Margin	10.16%	12.42%	11.01%
Operating Margin	5.38%	8.41%	7.78%
EBIT Margin	5.34%	8.27%	7.25%
Profit (Net Income) Margin	1.01%	4.70%	4.07%
Tax Burden Percent	88.64%	96.31%	92.71%
Interest Burden Percent	21.29%	59.05%	60.58%
Effective Tax Rate	11.36%	3.69%	7.29%
Return on Invested Capital (ROIC)	0.00%	12.60%	6.54%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	7.25%	2.39%
Return on Net Nonoperating Assets (RNNOA)	0.00%	643.14%	5.24%
Return on Equity (ROE)	0.00%	655.74%	11.77%
Cash Return on Invested Capital (CROIC)	0.00%	-187.41%	15.82%
Operating Return on Assets (OROA)	0.00%	5.86%	5.53%
Return on Assets (ROA)	0.00%	3.34%	3.11%
Return on Common Equity (ROCE)	0.00%	28,949.21%	16.11%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	1,108	2,067	2,051
NOPAT Margin	4.77%	8.10%	7.21%
Net Nonoperating Expense Percent (NNEP)	0.00%	5.34%	4.15%
Return On Investment Capital (ROIC_SIMPLE)	-	12.53%	6.44%
Cost of Revenue to Revenue	74.67%	72.65%	73.56%
SG&A Expenses to Revenue	16.65%	16.11%	15.91%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	19.95%	18.94%	18.66%
Earnings before Interest and Taxes (EBIT)	1,240	2,110	2,060
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	2,361	3,169	3,130
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.00	0.39	3.17
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.27	0.25	1.20
Price to Earnings (P/E)	26.77	5.22	29.35
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	3.74%	19.15%	3.41%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.70	1.78
Enterprise Value to Revenue (EV/Rev)	0.00	0.90	1.87
Enterprise Value to EBITDA (EV/EBITDA)	0.00	7.23	16.99
Enterprise Value to EBIT (EV/EBIT)	0.00	10.87	25.82
Enterprise Value to NOPAT (EV/NOPAT)	0.00	11.09	25.94
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	12.96	30.50
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	10.72
Leverage & Solvency	-	-	-
Debt to Equity	0.00	45.07	0.65
Long-Term Debt to Equity	0.00	44.85	0.65
Financial Leverage	0.00	88.67	2.19
Leverage Ratio	0.00	98.30	3.79
Compound Leverage Factor	0.00	58.05	2.30
Debt to Total Capital	0.00%	97.83%	39.44%
Short-Term Debt to Total Capital	0.00%	0.46%	0.24%
Long-Term Debt to Total Capital	0.00%	97.37%	39.20%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	2.17%	26.84%
Common Equity to Total Capital	0.00%	95.84%	33.71%
Debt to EBITDA	0.00	5.20	4.01
Net Debt to EBITDA	0.00	5.14	3.39
Long-Term Debt to EBITDA	0.00	5.18	3.99
Debt to NOPAT	0.00	7.98	6.13
Net Debt to NOPAT	0.00	7.88	5.18
Long-Term Debt to NOPAT	0.00	7.94	6.09
Altman Z-Score	0.00	1.29	2.23
Noncontrolling Interest Sharing Ratio	0.00%	-4,314.75%	-36.86%
Liquidity Ratios	-	-	-
Current Ratio	0.00	3.39	4.29
Quick Ratio	0.00	1.40	2.20
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-30,752	4,962
Operating Cash Flow to CapEx	612.73%	499.72%	390.16%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.71	0.76
Accounts Receivable Turnover	0.00	7.92	8.42
Inventory Turnover	0.00	4.16	4.53
Fixed Asset Turnover	0.00	5.55	6.07
Accounts Payable Turnover	0.00	21.32	22.86
Days Sales Outstanding (DSO)	0.00	46.06	43.34
Days Inventory Outstanding (DIO)	0.00	87.77	80.50
Days Payable Outstanding (DPO)	0.00	17.12	15.97
Cash Conversion Cycle (CCC)	0.00	116.72	107.87
Capital & Investment Metrics	-	-	-
Invested Capital	0.00	32,819	29,908
Invested Capital Turnover	0.00	1.55	0.91
Increase / (Decrease) in Invested Capital	0.00	32,819	-2,911
Enterprise Value (EV)	0.00	22,926	53,191
Market Capitalization	6,265	6,265	34,020
Book Value per Share	$0.00	$74.79	$13.26
Tangible Book Value per Share	$0.00	($29.93)	($13.87)
Total Capital	0.00	16,860	31,847
Total Debt	0.00	16,494	12,561
Total Long-Term Debt	0.00	16,416	12,484
Net Debt	0.00	16,295	10,622
Capital Expenditures (CapEx)	275	354	447
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	5,711	6,327
Debt-free Net Working Capital (DFNWC)	0.00	5,910	8,266
Net Working Capital (NWC)	0.00	5,832	8,189
Net Nonoperating Expense (NNE)	874	867	894
Net Nonoperating Obligations (NNO)	0.00	32,453	10,622
Total Depreciation and Amortization (D&A)	1,121	1,059	1,070
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	22.39%	22.25%
Debt-free Net Working Capital to Revenue	0.00%	23.17%	29.07%
Net Working Capital to Revenue	0.00%	22.86%	28.80%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($0.01)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	810M
Adjusted Diluted Earnings per Share	$0.00	$0.00	($0.01)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	810M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	1.31B
Normalized Net Operating Profit after Tax (NOPAT)	1,108	2,067	2,051
Normalized NOPAT Margin	4.77%	8.10%	7.21%
Pre Tax Income Margin	1.14%	4.88%	4.39%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	48.72%	126.50%	44.77%
Augmented Payout Ratio	48.72%	128.17%	221.00%

This table displays calculated financial ratios and metrics derived from Medline's official financial filings.

Metric	Q1 2025	Q1 2026
Period end date	3/29/2025	3/28/2026
DEI Shares Outstanding	0.00	1,313,693,412.00
DEI Adjusted Shares Outstanding	0.00	1,313,693,412.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.10
Growth Metrics	-	-
Revenue Growth	0.00%	10.66%
EBITDA Growth	0.00%	-14.57%
EBIT Growth	0.00%	-22.08%
NOPAT Growth	0.00%	-36.28%
Net Income Growth	0.00%	-25.78%
EPS Growth	0.00%	0.00%
Operating Cash Flow Growth	0.00%	-39.59%
Free Cash Flow Firm Growth	0.00%	0.00%
Invested Capital Growth	0.00%	0.00%
Revenue Q/Q Growth	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%
Profitability Metrics	-	-
Gross Margin	27.45%	25.04%
EBITDA Margin	12.19%	9.41%
Operating Margin	8.59%	5.74%
EBIT Margin	8.25%	5.81%
Profit (Net Income) Margin	4.85%	3.25%
Tax Burden Percent	95.27%	82.13%
Interest Burden Percent	61.68%	68.15%
Effective Tax Rate	4.73%	17.87%
Return on Invested Capital (ROIC)	0.00%	9.26%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	7.17%
Return on Net Nonoperating Assets (RNNOA)	0.00%	3.83%
Return on Equity (ROE)	0.00%	13.09%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	4.34%
Return on Assets (ROA)	0.00%	2.43%
Return on Common Equity (ROCE)	0.00%	7.62%
Return on Equity Simple (ROE_SIMPLE)	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	544	347
NOPAT Margin	8.19%	4.71%
Net Nonoperating Expense Percent (NNEP)	0.00%	2.08%
Return On Investment Capital (ROIC_SIMPLE)	-	1.09%
Cost of Revenue to Revenue	72.55%	74.96%
SG&A Expenses to Revenue	16.10%	16.70%
R&D to Revenue	0.00%	0.00%
Operating Expenses to Revenue	18.86%	19.30%
Earnings before Interest and Taxes (EBIT)	548	427
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	810	692
Valuation Ratios	-	-
Price to Book Value (P/BV)	0.00	3.03
Price to Tangible Book Value (P/TBV)	0.00	0.00
Price to Revenue (P/Rev)	0.00	1.17
Price to Earnings (P/E)	0.00	35.32
Dividend Yield	0.00%	0.00%
Earnings Yield	0.00%	2.83%
Enterprise Value to Invested Capital (EV/IC)	0.00	1.77
Enterprise Value to Revenue (EV/Rev)	0.00	1.80
Enterprise Value to EBITDA (EV/EBITDA)	0.00	17.44
Enterprise Value to EBIT (EV/EBIT)	0.00	27.09
Enterprise Value to NOPAT (EV/NOPAT)	0.00	28.47
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	35.64
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00
Leverage & Solvency	-	-
Debt to Equity	0.00	0.65
Long-Term Debt to Equity	0.00	0.65
Financial Leverage	0.00	0.53
Leverage Ratio	0.00	2.02
Compound Leverage Factor	0.00	1.37
Debt to Total Capital	0.00%	39.38%
Short-Term Debt to Total Capital	0.00%	0.24%
Long-Term Debt to Total Capital	0.00%	39.14%
Preferred Equity to Total Capital	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	25.30%
Common Equity to Total Capital	0.00%	35.31%
Debt to EBITDA	0.00	4.17
Net Debt to EBITDA	0.00	3.43
Long-Term Debt to EBITDA	0.00	4.15
Debt to NOPAT	0.00	6.81
Net Debt to NOPAT	0.00	5.60
Long-Term Debt to NOPAT	0.00	6.77
Altman Z-Score	0.00	2.09
Noncontrolling Interest Sharing Ratio	0.00%	41.74%
Liquidity Ratios	-	-
Current Ratio	0.00	4.41
Quick Ratio	0.00	2.33
Cash Flow Metrics	-	-
Free Cash Flow to Firm (FCFF)	0.00	-29,338
Operating Cash Flow to CapEx	695.92%	429.17%
Free Cash Flow to Firm to Interest Expense	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00
Efficiency Ratios	-	-
Asset Turnover	0.00	0.75
Accounts Receivable Turnover	0.00	7.93
Inventory Turnover	0.00	4.49
Fixed Asset Turnover	0.00	6.12
Accounts Payable Turnover	0.00	23.18
Days Sales Outstanding (DSO)	0.00	46.02
Days Inventory Outstanding (DIO)	0.00	81.21
Days Payable Outstanding (DPO)	0.00	15.75
Cash Conversion Cycle (CCC)	0.00	111.48
Capital & Investment Metrics	-	-
Invested Capital	0.00	29,685
Invested Capital Turnover	0.00	1.96
Increase / (Decrease) in Invested Capital	0.00	29,685
Enterprise Value (EV)	0.00	52,528
Market Capitalization	6,265	34,115
Book Value per Share	$0.00	$8.58
Tangible Book Value per Share	$0.00	($8.01)
Total Capital	0.00	31,921
Total Debt	0.00	12,572
Total Long-Term Debt	0.00	12,495
Net Debt	0.00	10,336
Capital Expenditures (CapEx)	98	96
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	6,485
Debt-free Net Working Capital (DFNWC)	0.00	8,721
Net Working Capital (NWC)	0.00	8,644
Net Nonoperating Expense (NNE)	222	108
Net Nonoperating Obligations (NNO)	0.00	10,336
Total Depreciation and Amortization (D&A)	262	265
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	22.25%
Debt-free Net Working Capital to Revenue	0.00%	29.93%
Net Working Capital to Revenue	0.00%	29.66%
Earnings Adjustments	-	-
Adjusted Basic Earnings per Share	$0.00	$0.16
Adjusted Weighted Average Basic Shares Outstanding	0.00	819.08M
Adjusted Diluted Earnings per Share	$0.00	$0.16
Adjusted Weighted Average Diluted Shares Outstanding	0.00	824.84M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	1.31B
Normalized Net Operating Profit after Tax (NOPAT)	544	347
Normalized NOPAT Margin	8.19%	4.71%
Pre Tax Income Margin	5.09%	3.96%
Debt Service Ratios	-	-
EBIT to Interest Expense	0.00	0.00
NOPAT to Interest Expense	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00
Payout Ratios	-	-
Dividend Payout Ratio	0.00%	49.16%
Augmented Payout Ratio	0.00%	238.45%

Financials Breakdown Chart

Medline Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Medline's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Medline's net income appears to be on an upward trend, with a most recent value of $1.16 billion in 2025, rising from $234 million in 2023. The previous period was $1.20 billion in 2024. See Medline's forecast for analyst expectations on what's next for the company.

Medline's total operating income in 2025 was $2.21 billion, based on the following breakdown:

Total Gross Profit: $7.52 billion
Total Operating Expenses: $5.31 billion

Over the last 2 years, Medline's total revenue changed from $23.23 billion in 2023 to $28.43 billion in 2025, a change of 22.4%.

Medline's total liabilities were at $19.20 billion at the end of 2025, a 1.3% decrease from 2024, and a 1.3% decrease since 2024.

In the past 1 years, Medline's cash and equivalents has ranged from $199 million in 2024 to $1.94 billion in 2025, and is currently $1.94 billion as of their latest financial filing in 2025.

Over the last 2 years, Medline's book value per share changed from 0.00 in 2023 to 13.26 in 2025, a change of 1,325.6%.

Related Companies

Financial statements for NASDAQ:MDLN last updated on 5/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medline (MDLN) Financials

Financials Breakdown Chart

Medline Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medline (MDLN) Financials

Annual Income Statements for Medline

Quarterly Income Statements for Medline

Annual Cash Flow Statements for Medline

Quarterly Cash Flow Statements for Medline

Annual Balance Sheets for Medline

Quarterly Balance Sheets for Medline

Annual Metrics And Ratios for Medline

Quarterly Metrics And Ratios for Medline

Financials Breakdown Chart

Medline Financials - Frequently Asked Questions

When does Medline's fiscal year end?

How has Medline's net income changed over the last 2 years?

What is Medline's operating income?

How has Medline's revenue changed over the last 2 years?

How much debt does Medline have?

How much cash does Medline have?

How has Medline's book value per share changed over the last 2 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools